On January 29, 2016 the share price was:
$2.0800
Over 7 years later it’s now:
$.069 a share as of Friday, September 15, 2023. I think it could break $0.70 today. We’ll see and I hope it does go and more.
I was right and sincere to criticize how media and investor relations were being handled at NWBO in 2016. Their seemingly broken promise to proceed undeterred after Dr. Buzdar criticized them publicly for good communication is still bitter especially since smart shareholders knew what would happen just now how bad it would get. Now NWBO is slick with words so maybr thru can say they meant undeterred on the science but last so checked Dr. Buzdar was not demanding they shut down Direct but only (improperly demanding) that they shut up about it.
So yes, the biggest thing I really got wrong was how bad they would let the share price get and how long this whole thing could be dragged out by these folks with little change in communication before they finally started a hint of reform in August 2023 by providing a fairly clear timeframe on submission.
The next thing I got wrong was how very little big catalysts would matter for the SP if NWBO made such a desultory effort at media relations and engaging with investors when the catalysts came. I naively thought that something like TLD would finally be it or even that first long delayed JA (which was supposed to be in a big journal) or even a conference presentation would grab media attention despite NWBO’s reticence and that would be that. If nothing else I thought patients might notice a milestone like TLD and start pushing if no one else would though this was a long shot.
The narrative of spoofing has been advanced very late in the game and maybe a jury will make a finding of fact that the narrative has truth to it and maybe that will be a partial explanation and the company cash in that way or via a settlement and maybe get DCVax Direct moving again. Maybe, maybe not.
Even so, it is widely and well understood that pre-revenue biotechs that fund themselves via dilution mostly have to support their SP by executing on catalysts and just as importantly, consistently communicating the company’s story to shareholders and potential shareholders of the share price is to avoid a natural drift downward as the share count is inflated but no revenue or little revenue comes in.
Hopefully NWBO management is finally listening to shareholders and if so you will see the good results that come from better communication since as seem, big catalysts do little without communication.
